Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
Neeta B. Amin(Pfizer (United States)), Santos Carvajal‐Gonzalez(Pfizer (United States)), Julie J. Purkal(Pfizer (United States)), Tong Zhu(Pfizer (United States)), Collin Crowley(Pfizer (United States)), Sylvie Perez(Pfizer (United States)), Kristin Chidsey(Pfizer (United States)), Albert M. Kim(Pfizer (United States)), Bryan Goodwin(Pfizer (United States))
Cited by 72Open Access
Abstract
< 0.05). Moreover, magnetic resonance imaging using proton density fat fraction showed that PF-06427878 1500 milligrams per day reduced hepatic steatosis in healthy adult participants. Our findings highlight DGAT2 inhibition by a small, potent, selective compound as a potential therapeutic approach for the treatment of NASH.
Related Papers
No related papers found
Powered by citation graph analysis